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Coagulation Abnormalities Following NexoBrid Use: 
A Case Report
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Patients with major burn injury undergo a series of pathophysiologic changes that 
begin with a systemic inflammatory response and coagulation abnormalities, similar 
to those experienced by patients with sepsis or severe trauma. Coagulation changes 
in patients with burns are generally characterized by procoagulant abnormalities, 
but alterations in fibrinolysis and anticoagulation factors have also been observed. 
Around 40% of patients with major burn show changes on standard coagulation 
tests, and these have been related to the severity of the lesions, smoke inhalation, and 
administration of intensive fluid resuscitation therapy. Current surgical techniques 
for debridement of burn lesions are aggressive and associated with considerable 
blood loss. A fast-acting selective enzymatic debriding agent based on bromelain has 
been recently developed. NexoBrid is indicated for removing eschar in adults with 
deep partial- and full-thickness thermal burns. A potential effect of oral bromelain 
on hemostasis has been described, but it is uncertain whether NexoBrid application 
has a clinically relevant impact in this regard. We present the clinical case of a patient 
with burns who showed a coagulation abnormality shortly after NexoBrid use.
Patients with major burn injuries experience a se-
ries of pathophysiologic changes, beginning with a 
systemic inflammatory response1 and coagulation 
abnormalities that resemble what occurs in patients 
with sepsis or severe traumatic injury. The coagula-
tion disturbance in patients with burn is character-
ized by procoagulant changes, but abnormalities in 
fibrinolysis and factors related with anticoagulation 
have also been observed.2 Overall, around 40% of 
patients with major burn show changes (most often 
the prothrombin time) on standard coagulation 
 testing in the first 24 hours. These abnormalities are 
related to the severity of the burn, smoke inhalation, 
and administration of intensive fluid therapy.3–5
Current surgical techniques for burn wound de-
bridement are associated with considerable blood 
loss due to the aggressive action on tissues. To im-
prove this situation, a fast-acting, selective enzy-
matic debridement agent based on bromelain was 
recently developed (NexoBrid; MediWound Ltd, 
Israel). This product is indicated for removing es-
char in adults with deep partial- and full-thickness 
thermal burns. As compared to the standard of 
care, surgical debridement, enzymatic debride-
ment seems to result in a lower procedure-related 
blood loss.6 However, NexoBrid has been imple-
mented in  clinical practice only recently, and there 
is little information regarding its management, 
safety, and efficacy. According to the product in-
sert, orally administered bromelain may have an 
effect on hemostasis, but it is unknown whether 
NexoBrid application could have a clinically rel-
evant impact in this regard,7 such as an increased 
risk of bleeding. During clinical development of 
the product, there was no evidence indicating this 
potential effect.
Studies published by Rosenberg et al, in 2014 and 
2015, found no coagulation-related adverse effects in 
patients receiving NexoBrid,8 and the only reference to 
analytical parameters was in relation to bleeding, where 
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it was concluded that the drop in hemoglobin and he-
matocrit was smaller in patients receiving NexoBrid 
than in those undergoing surgical debridement.6
NexoBrid is applied on the burn and left to act for a 
period of 4 hours. Effective analgesia is required while 
it is being applied, during the time it acts, and when it 
is removed. Locoregional anesthesia or deep sedation 
can be used for this purpose, depending on the mag-
nitude of the lesions sustained. Here, we report the 
case of a patient with burn injury who experienced a 
coagulation abnormality following NexoBrid use.
CLINICAL CASE
A 41-year-old man, weighing 89 kg, tobacco and 
cannabis smoker, reporting moderate alcohol con-
sumption, occasional cocaine use, and no medica-
tion allergies or medical history of interest, sustained 
a burn injury caused by an industrial aerosol explo-
sion in the factory where he was working. At the 
initial evaluation, the emergency services noted fa-
cial burns and dysphonia. Orotracheal intubation 
was performed, which disclosed mild glottic edema. 
After the airway had been secured, the patient was 
transferred to our center in a state of hemodynamic 
and respiratory stability. Before arriving at our hos-
pital, he received 2000 ml of crystalloid infusion.
On admission, the total extent of the burn injury 
was estimated using the Lund and Browder chart 
(Figure 1). The patient had burns on 15% of TBSA, 
located on the forearms and hands, upper third of 
the face and scalp, and both knees. The lesions were 
classified as mainly intermediate/deep second-de-
gree burns with some areas of erythema on the lower 
third of the face and anterior cervical region. There 
were no third-degree burn areas.
Figure 1. Lund and Browder chart for adults
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The calculated Acute Burn Severity Index was 7, 
and the estimated risk of death was between 10 and 
20%. Analytic determinations on admission showed 
no abnormalities (Table 1). Initial fluid resuscitation 
was performed according to the Parkland formula, 
corrected to maintain diuresis above 0.5 ml/kg/h. 
The patient received 1600 ml of balanced crystalloid 
(Ringer’s lactate) in the first 6 hours.
On day 1 following admission and based on the 
characteristics of the burns, it was decided to per-
form NexoBrid enzymatic debridement on the fore-
arms, the areas with the deepest burns, accounting 
for 6% of the TBSA. As the patient was still intu-
bated, it was only necessary to deepen the sedation 
and analgesia to perform the enzymatic debridement 
technique. The product was applied and left in place 
for 4 hours. Two hours after its removal, the patient 
showed central hyperthermia of 40°C without he-
modynamic instability. In response to this develop-
ment, blood, urine, and tracheal aspirate samples 
were taken for culture, and antibiotic therapy was 
started, even though the hyperthermia could have 
been related to NexoBrid application.7
Analytic controls performed at 24 hours after 
debridement disclosed decreased coagulation activ-
ity: prothrombin time ratio 1.78 and activated par-
tial thromboplastin time ratio 1.24. The patient 
showed no signs of active bleeding, platelet count 
had dropped somewhat (110,000  ×  106/l), and 
hemoglobin measured 9.8 g/dl. Because of the dis-
crepancy relative to the baseline values, the analy-
sis was repeated, and the changes were confirmed. 
Intravenous single dose of 10-mg phytomenadione 
was then administered, and in 24 hours, the coag-
ulation parameters had returned to normal values. 
The patient showed no other coagulation changes in 
the following analytic determinations. Since the time 
of hospital admission, 9840  ml of crystalloids and 
800 ml of albumin 20% had been infused.
Initial extubation could not be performed due 
to hypoxemia secondary to left lung basal atelecta-
sia. After respiratory therapy, the patient could be 
extubated on day 4 following admission, showing 
mild, clinically well-tolerated postextubation hypox-
emia. Chest radiographs showed signs of vascular 
redistribution with bilateral infiltrates, and the tra-
cheal aspirate tested positive for cloxacillin-sensitive 
Staphylococcus aureus. No other lung injuries were 
found. A diagnosis of tracheobronchitis and suspected 
smoke inhalation was established, and combined 
treatment with antibiotics, diuretics, and Optiflow 
oxygen therapy was administered. The hypoxemia 
gradually improved and had resolved at 7 days. The 
total positive fluid balance was 17.239 ml. The pa-
tient additionally received antibiotics for a central ve-
nous line infection and chlormethiazole for alcohol 
abstinence. His clinical course was favorable, and he 
was discharged on day 16 following admission.
LITERATURE REVIEW OF 
BROMELAIN USE
A PubMed search was performed, and four arti-
cles related to NexoBrid use were retrieved.6,8–10 We 
excluded one article9 because it focused on the use 
of a bromelain derivate for enzymatic fasciotomy in 
Dupuytren’s disease. Among the remaining three ar-
ticles, the most recent one reported the clinical case 
of a 14-year-old patient satisfactorily treated with 
NexoBrid after sustaining a burn injury due to explo-
sion of the lithium battery in his mobile phone. No 
treatment-related adverse effects were detected.10
Rosenberg et  al published a multicenter phase-3 
clinical trial including 26 centers in 13 different 
countries.8 Patients 4 to 44 years of age with burns 
covering 5 to 30% of BSA were included. The results 
showed no coagulation-related adverse effects.
In their study in 2015, the same authors reviewed 
the findings of seven clinical studies reporting 
NexoBrid use.6 They concluded that enzymatic de-
bridement completely eliminates eschar without 
injuring surrounding tissues, exposing a viable dermis 
bed. In addition, it was found to reduce the increase 





(× 106/l) PT (%) PT Ratio aPTT Ratio Fibrinogen (g/l)
29 October (Day 1, before 
NexoBrid use)
15 165,000 76 1.19 1.01 3.58
30 October, 8:56 am 9.8 110,000 43 1.78 1.24 3.98
30 October, 11:50 am 47 1.74 1.1 4.64
31 October 10.5 126,000 80 1.16 0.94 5.85
1 November 9.7 149,000 87 1.10 0.81 5.86
aPTT, activated partial thromboplastin time; PT, prothrombin time.
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burns of the extremities. No reference to coagulation 
abnormalities was made in this second study.
DISCUSSION
Coagulation changes are not uncommon in 
patients with burn injury. Acute burn-induced 
coagulopathy is a well-described entity similar to 
the acute coagulopathy occurring in patients with 
trauma. According to Sherren et al,3 around 40% of 
patients with major burn have coagulopathy at hos-
pital admission, which correlates with the severity of 
the burn and is associated with the extension of the 
injury, smoke inhalation, the Acute Burn Severity 
Index, and the total burn thickness.
The patient presented here had burns more than 
15% of TBSA; hence, he cannot be considered a pa-
tient with major burn. He would have a low prob-
ability of showing coagulation abnormalities related 
to the thermal lesion, and this was supported by the 
normal values found in the analyses at admittance. 
Smoke inhalation is another factor favoring acute 
burn-induced coagulopathy. In our clinical expe-
rience, patients who experience smoke inhalation 
have increased fluid requirements due to the lesion 
itself, and this could lead to dilution coagulopathy. 
Nonetheless, although our patient had an inhalation 
lesion, he did not require more than 4.4 ml/kg/h of 
fluids in the first 24 hours, an amount close to the 
value given in standard protocols and which should 
not lead to dilution coagulopathy.
Another cause of justifiable coagulopathy would 
have been a septic state but other than atelectasia and 
tracheobronchitis, no other lung or systemic injuries 
were found to qualify our patient as septic.
The acute coagulation abnormality exhibited by 
our patient manifested soon after treatment with 
NexoBrid, and this could be interpreted as a causal 
relationship. In the product insert, coagulopathy is 
mentioned as a potential adverse effect of NexoBrid 
use, but it has not been described in any of the 
patients treated with this agent. Reduced platelet 
aggregation and plasma fibrinogen concentrations, 
and moderately increased prothrombin and partial 
thromboplastin times have been reported as pos-
sible effects following oral bromelain administra-
tion. Data from in vitro and experimental animal 
studies suggest that bromelain may also enhance 
fibrinolysis. During the clinical development phase 
of NexoBrid, there were no findings to indicate 
an increased risk of bleeding at the debridement 
site,7 but the study made no reference to analytic 
changes. In our unit, viscoelastic techniques were 
not available to further evaluate the analytic abnor-
malities observed.
Our patient additionally showed hyperthermia 
following enzymatic debridement. We can reason-
ably discard a systemic cause for this, as tracheo-
bronchitis and central line infection were localized. 
Operating room conditions might also be the 
cause of hyperthermia, but our patient never re-
quired surgery. In this case, we attribute the hy-
perthermia to NexoBrid itself, as is also described 
in the product insert. The mechanism causing this 
effect is unknown.
In light of the observations in our patient, we be-
lieve it may be advisable to monitor possible coagu-
lation-related adverse effects in patients treated with 
NexoBrid. It may also be appropriate to use this 
product with caution in patients receiving antiplate-
let or anticoagulant therapy, particularly if locore-
gional anesthesia techniques are used for performing 
the enzyme debridement technique.
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